Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Caribou Biosciences Q3 EPS $(0.12) Beats $(0.42) Estimate, Sales $23.66M Beat $3.15M Estimate

Author: Benzinga Newsdesk | November 07, 2023 05:57pm
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.42) by 71.43 percent. This is a 72.73 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $23.66 million which beat the analyst consensus estimate of $3.15 million by 651.17 percent. This is a 616.38 percent increase over sales of $3.30 million the same period last year.

Posted In: CRBU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist